乳腺癌组织中miR-34a表达与新辅助化疗疗效、肿瘤病理特征、细胞增殖基因的相关性
摘要
目的研究乳腺癌组织中miR-34a表达与新辅助化疗疗效、肿瘤病理特征、细胞增殖基因的相关性。方法选取2013年5月-2017年2月在台州市中西医结合医院接受新辅助化疗的乳腺癌患者作为研究对象,收集乳腺癌组织及癌旁组织,测定miR-34a及细胞增殖基因的表达水平,判断化疗的近期疗效及远期疗效。结果乳腺癌组织中miR-34a的表达水平明显低于癌旁组织,Ki-67、PCNA、Cyclin D1的阳性表达率明显高于癌旁组织(P<0. 05)。TNMⅢ期乳腺癌组织中miR-34a的表达水平明显低于TNMⅠ～Ⅱ期乳腺癌组织(P<0. 05),淋巴结浸润乳腺癌组织中miR-34a的表达水平明显低于无淋巴结浸润的乳腺癌组织(P<0. 05)。乳腺癌组织中miR-34a高表达患者的治疗有效率、疾病控制率明显高于miR-34a低表达患者,无进展生存情况优于miR-34a低表达患者(P<0. 05)。miR-34a高表达的乳腺癌组织中Ki-67、PCNA、Cyclin D1的阳性表达率明显低于miR-34a低表达的乳腺癌组织(P<0. 05)。结论乳腺癌组织中miR-34a高表达患者的新辅助化疗效果更为理想,细胞增殖基因的表达更低。
引文
[1] Zhang L,Liao Y,Tang L. MicroRNA-34 family:a potential tumor suppressor and therapeutic candidate in cancer[J]. J Exp Clin Cancer Res,2019,38(1):53.
[2] Imani S,Wu RC,Fu J. MicroRNA-34 family in breast cancer:from research to therapeutic potential[J]. J Cancer,2018,9(20):3765-3775.
[3] Zhou Y,Ding BZ,Lin YP,et al. MiR-34a,as a suppressor,enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1[J]. Gene,2018,20(644):56-65.
[4] Orosz E,Kiss I,Gyngyi Z,et al. Expression of Circulating miR-155,miR-21,miR-221,miR-30a,miR-34a and miR-29a:comparison of colonic and rectal cancer[J]. In Vivo,2018,32(6):1333-1337.
[5] Kulda V,Svaton M,Mukensnabl P,et al. Predictive relevance of miR-34a,miR-224 and miR-342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy[J]. Oncol Lett,2018,15(1):592-599.
[6] Wu G,Li Z,Wang Y,et al. miR-34a Inhibits Cell Proliferation by Targeting SATB2 in Hepatocellular Carcinoma[J]. Biomed Res Int,2018,6(2018):2863902.
[7] Rui X,Zhao H,Xiao X,et al. MicroRNA-34a suppresses breast cancer cell proliferation and invasion by targeting Notch1[J]. Exp Ther Med,2018,16(6):4387-4392.
[8]王思琦,姜萍.乳腺癌患者新辅助化疗前后的磁共振成像表观扩散系数及其与肿瘤负荷的相关性[J].海南医学院学报,2018,24(9):945-948.
[9]郭欢,孔玲玲,邢力刚.乳腺癌新辅助化疗加改良根治术后辅助放疗的研究进展[J].浙江医学,2018,40(9):1011-1013,1019.
[10] Ye J,Li L,Feng P,et al. Downregulation of miR-34a contributes to the proliferation and migration of laryngeal carcinoma cells by targeting cyclin D1[J]. Oncol Rep,2016,36(1):390-398.
[11] Choi YS,Lee KE. The significance of miR-34a expression in endometrial carcinogenesis:correlation with expression of p16 and Ki-67proteins in endometrial cancers[J]. J Cancer Prev,2015,20(4):268-274.
[12] Wang F,Li Z,Xu L,et al. LIMD2 targeted by miR 34a promotes the proliferation and invasion of non small cell lung cancer cells[J]. Mol Med Rep,2018,18(5):4760-4766.
[13] Zhang Y,Pan Y,Xie C,et al. miR-34a exerts as a key regulator in the dedifferentiation of osteosarcoma via PAI-1-Sox2 axis[J].Cell Death Dis,2018,9(7):777.
[14] Guo JL,Gu SQ,Li Y,et al. Evaluation of clinical significance of endoglin expression during breast cancer and its correlation with ER and PCNA[J]. Eur Rev Med Pharmacol Sci,2017,21(23):5402-5407.
[15]谢莉莉,黄华.乳腺癌中PCNA和BCA-225蛋白表达与预后相关性研究[J].交通医学,2018,32(4):320-323.
[16]崔艳婷,谢小红,顾锡冬,等.乳腺癌患者MVD VEGF与Ki-67淋巴结转移的相关性分析[J].浙江临床医学,2018,20(1):12-14.
[17]王峰峰,朱佳,杨华伟,等. RSK4与Ki-67、cyclin D1、CXCR4、E-cadherin在乳腺癌裸鼠移植瘤中的相关性研究[J].中国癌症防治杂志,2018,10(2):136-141.
[18] Parvin T,Das C,Choudhury M,et al. Prognostic Utility of Cyclin D1 in Invasive Breast Carcinoma[J]. Indian J Surg Oncol,2019,10(1):167-173.
[2] Imani S,Wu RC,Fu J. MicroRNA-34 family in breast cancer:from research to therapeutic potential[J]. J Cancer,2018,9(20):3765-3775.
[3] Zhou Y,Ding BZ,Lin YP,et al. MiR-34a,as a suppressor,enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1[J]. Gene,2018,20(644):56-65.
[4] Orosz E,Kiss I,Gyngyi Z,et al. Expression of Circulating miR-155,miR-21,miR-221,miR-30a,miR-34a and miR-29a:comparison of colonic and rectal cancer[J]. In Vivo,2018,32(6):1333-1337.
[5] Kulda V,Svaton M,Mukensnabl P,et al. Predictive relevance of miR-34a,miR-224 and miR-342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy[J]. Oncol Lett,2018,15(1):592-599.
[6] Wu G,Li Z,Wang Y,et al. miR-34a Inhibits Cell Proliferation by Targeting SATB2 in Hepatocellular Carcinoma[J]. Biomed Res Int,2018,6(2018):2863902.
[7] Rui X,Zhao H,Xiao X,et al. MicroRNA-34a suppresses breast cancer cell proliferation and invasion by targeting Notch1[J]. Exp Ther Med,2018,16(6):4387-4392.
[8]王思琦,姜萍.乳腺癌患者新辅助化疗前后的磁共振成像表观扩散系数及其与肿瘤负荷的相关性[J].海南医学院学报,2018,24(9):945-948.
[9]郭欢,孔玲玲,邢力刚.乳腺癌新辅助化疗加改良根治术后辅助放疗的研究进展[J].浙江医学,2018,40(9):1011-1013,1019.
[10] Ye J,Li L,Feng P,et al. Downregulation of miR-34a contributes to the proliferation and migration of laryngeal carcinoma cells by targeting cyclin D1[J]. Oncol Rep,2016,36(1):390-398.
[11] Choi YS,Lee KE. The significance of miR-34a expression in endometrial carcinogenesis:correlation with expression of p16 and Ki-67proteins in endometrial cancers[J]. J Cancer Prev,2015,20(4):268-274.
[12] Wang F,Li Z,Xu L,et al. LIMD2 targeted by miR 34a promotes the proliferation and invasion of non small cell lung cancer cells[J]. Mol Med Rep,2018,18(5):4760-4766.
[13] Zhang Y,Pan Y,Xie C,et al. miR-34a exerts as a key regulator in the dedifferentiation of osteosarcoma via PAI-1-Sox2 axis[J].Cell Death Dis,2018,9(7):777.
[14] Guo JL,Gu SQ,Li Y,et al. Evaluation of clinical significance of endoglin expression during breast cancer and its correlation with ER and PCNA[J]. Eur Rev Med Pharmacol Sci,2017,21(23):5402-5407.
[15]谢莉莉,黄华.乳腺癌中PCNA和BCA-225蛋白表达与预后相关性研究[J].交通医学,2018,32(4):320-323.
[16]崔艳婷,谢小红,顾锡冬,等.乳腺癌患者MVD VEGF与Ki-67淋巴结转移的相关性分析[J].浙江临床医学,2018,20(1):12-14.
[17]王峰峰,朱佳,杨华伟,等. RSK4与Ki-67、cyclin D1、CXCR4、E-cadherin在乳腺癌裸鼠移植瘤中的相关性研究[J].中国癌症防治杂志,2018,10(2):136-141.
[18] Parvin T,Das C,Choudhury M,et al. Prognostic Utility of Cyclin D1 in Invasive Breast Carcinoma[J]. Indian J Surg Oncol,2019,10(1):167-173.